



**Security
Screening**



**Medical
Imaging**



**Nuclear
Detection**

Kromek Group plc

Shares / Cenkos Innovators & Investors Forum

Kromek is a radiation detection technology company operating globally in three high value markets:

- Medical Imaging
 - Security Screening
 - Nuclear Detection
-
- **X-ray and gamma ray imaging is going digital and colour as well, and CZT is an enabling technology**
 - **Two-legged business model:**
 - Supplier of OEM subsystems
 - Kromek branded end user products
 - **Significant revenue growth** in past two years
 - **2 manufacturing sites:** (UK + US), ~100 employees, 265+ patents issued and pending
 - **Blue chip customer base** – Established and diversified customer base, including government agencies and global OEMs

The world is changing...




...photography and television have gone **digital** and **colour**




X-ray and gamma ray imaging is going **digital**
and **colour** as well, and **CZT** is an enabling technology



Advanced sensor materials to detection solutions





Networked detectors

- Kromek technology chosen in competitive process to provide real-time networked monitoring of radiation risk
- DARPA trial started June 2014 - \$1.2m 12 month contract. \$1.1m contract extended in Jan 2015
- Initial phase I development programme ongoing – target cost per unit \$400
- April 2015 – contract worth \$2.0m to provide an accelerated phase 1b trial to deliver 1,000 units of a modified small form factor version of D3 product
- In October, DARPA announced intention to award sole source contract to Kromek for up to 12,000 units

\$1bn+
Kromek's
addressable market



Nuclear
detection

Nuclear Safeguard – D3S a portable combined gamma neutron detector which is networked via mobile phone linked to a central server. Prevention against nuclear terrorism threat.



SPECT - Single Photon Emission Computed Tomography



SPECT – Nuclear Medicine diagnostic imaging where the patient is injected with a radio-pharmaceutical. The pharmaceutical then congregates at tumour sites.

- Three key vendors account for 75% of market
- In April 2014, Kromek announced a long term contract with an established Chinese manufacturer who was given exclusive rights over Chinese territories
- 3 current customers



Advantages of using CZT


Reduced dose rate

Reduced scan time

Higher resolution and specificity

Improved image quality enables more accurate and earlier detection of cancer, faster treatment cycle so lower cost of care, with lower overall radiation exposure


\$100m+
Kromek's
addressable market



Conventional
mammography

vs

CZT-based image
detecting carcinoma
not visible on
conventional scan



CT - Computed Tomography



CT – (photon counting) is an x-ray based diagnostic imaging technique where slices of images are taken and then can be rendered into a 3D image – for detection of cancers, cardiac and other pathologies.



With CZT - improved image quality enables more accurate diagnosis and greater efficiency of treatment – and so lower cost of care


Advantages of using CZT

Dose reduction and higher patient output

High specificity providing better contrast

Accurate imaging for blood-flow and drug take-up

- The biggest x-ray-based diagnostic modality - \$5.1bn/yr global market
- GE, Siemens, Toshiba and Philips own over 80% of global market
- Successful delivery of \$5.3m exclusive development contract with a top four global OEM in the CT market
- Executing on the strategy to be the leading supplier of detection modules in the market



- Well positioned to capture the large existing opportunities in its three key target areas of CT, SPECT and portable advanced radiation detectors – significant new opportunities identified in all three target areas
- An expanded and diversified customer base in all three market segments – security screening, medical imaging and nuclear detection
- Continuing progress with new and existing global OEM customers, and the doubling of manufacturing capacity, provides an excellent foundation for future growth
- Number of multi year contracts signed during the period provides good visibility of revenue for current and next fiscal year
- Established new channels to market and continue to make progress in developing further channel partners
- Revenue visibility is significantly higher than the equivalent period last year providing a positive outlook for this and the next fiscal year



Thank you



Kromek Group Headquarters

NETPark
Thomas Wright Way
Sedgefield
County Durham
TS21 3FD UK

T: +44 (0) 1740 626060

F: +44 (0) 1740 626061

E: sales@kromek.com

W: www.kromek.com

UK Operations



Neutron R&D Centre
Huddersfield, UK

US Operations



NOVA R&D Inc
California, USA



eV Products Inc
Pennsylvania, USA